science

Lirentelimab

Lirentelimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Lirentelimab rather than just read about it. In short: Lirentelimab (called AK002 during preclinical development) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It was discovered and developed by Allakos.

Key takeaways

Lirentelimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Lirentelimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Lirentelimab from memory before moving on to harder problems.

Reference excerpt

Lirentelimab (called AK002 during preclinical development) is a humanized nonfucosylated monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). It was discovered and developed by Allakos. Allakos tested it several conditions driven by overactivation of eosinophils and mast cells but after it failed in two Phase II trials in 2024, Allakos stopped working on it.

Description Lirentelimab is a humanized, nonfucosylated IgG1 monoclonal antibody that targets Siglec-8; it removes eosinophils by triggering natural killer cells to kill them. Siglec-8 is an inhibitory receptor present on eosinophils and mast cells, with low level expression on basophils. Interleukin-5, granulocyte-macrophage colony stimulating factor, and interleukin-33 enhance anti-Siglec-8 mediated destruction of eosinophils. Lirentelimab inhibits mast cells' IgE-mediated degranulation and de novo synthesis of prostaglandin D2 in vitro.

Research Lirentelimab has been studied in clinical trials for conditions in which eosinophils are overactive - for example in chronic spontaneous urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. In January 2025, after the drug candidate failed in a phase II trial in atopic dermatitis and in a phase IIb study in chronic spontaneous urticaria, the company developing it, Allakos, ceased development of lirentelimbab. In 2025 Allakos and its assets were acquired by Concentra Biosciences, controlled by Tang Capital Management.

References

External links "Lirentelimab". Drug Information Portal. U.S. National Library of Medicine. 2022-08-16. Archived from the original on December 18, 2024.

Worked examples

Example 1 — a first encounter with Lirentelimab

Start with the simplest possible case. Write down what Lirentelimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Lirentelimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Lirentelimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Lirentelimab

In research: Lirentelimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Lirentelimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Lirentelimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Lirentelimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Lirentelimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Lirentelimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Lirentelimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Lirentelimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Lirentelimab in simple terms?

Why does Lirentelimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Lirentelimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Lirentelimab.